Search
Menu
Home
HTB
2023
March
HTB
March 2023
Contents
Editorial
HTB March 2023 (10 March 2023)
Supporting Ukraine
Conference reports
30th Conference on Retroviruses and OIs (CROI 2023): first reports
CROI 2023: Pipeline HIV drugs and formulations for treatment and PrEP
CROI 2023: Six-monthly ART – lenacapavir + dual bNAbs maintains undetectable viral load for 26 weeks after single doses
CROI 2023: Other lenacapavir studies – experienced and naive updates, the dosing window, HIV-2 and PrEP
CROI 2023: Similar PK profile for thigh vs gluteal CAB/RPV-LA injections: accidental intravenous injection
CROI 2023: Efficacy of N6LS monotherapy correlated with baseline factors
CROI 2023: CAB/RPV-LA levels are not reduced after switching from efavirenz
CROI 2023: Yet more evidence for recycled tenofovir and 3TC or FTC with dolutegravir in second-line: 48 week results from the D2EFT study
CROI 2023: Point-of-care testing for mothers and infants: results from the LIFE study
CROI 2023: Bone density profiles for CAB-LA vs TDF/FTC oral PrEP in young adults
CROI 2023: Single dose doxycycline as PEP for STIs (doxy-PEP): five studies
CROI 2023: Severe mpox outcomes with a low CD4 count and detectable viral load: a new AIDS-defining condition?
Cure-related research
The Düsseldorf patient HIV cure case published in Nature Medicine
Treatment advocacy
UK-CAB online training: webinar programme every two weeks
New community platform on HIV and mental health: in 10 EU languages
PDFs
HTB: no. 3 (March 2023) PDF download
HTB RSS
Current issues
October 2024
September 2024
August 2024
Back issues
Special report
HIV diagnoses in England jump by 51% in 2023: missing targets and highlighting disparities in access to care
6 October 2024
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage